\
&
Contact us
\
&
Contact us
This was 4 months ago
LocationHybrid (Brussels & live stream)
The Commission will organise an info day on the upcoming Cluster 3 calls on 4 March 2026.
This information-day event will highlight research topics covered within the 2026 calls for proposals in Horizon Europe Cluster 3 “civil security for society” that offer funding opportunities to research institutions, universities, industries, SMEs, civil society organizations and relevant security practitioners and stakeholders.
The event will cover key areas such as disaster-resilient societies, fight against crime and terrorism, border management, cybersecurity, and infrastructure protection. Participants will also benefit from practical information on how to apply, as well as opportunities to network and build consortia for future project proposals.
More information on the event, the agenda and the possibility to register can be found on the event website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
